Pyxis Oncology, Inc. filed a Form 8-K on November 19, 2026, disclosing updated clinical data from its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma, with a data cutoff of October 14, 2026.

Key Highlights

  • Confirmed objective response rate (cORR): 39% overall in 33 evaluable patients as of October 14, 2026.
  • Disease control rate (DCR): 94% across all 33 patients in the study.
  • Median progression-free survival (mPFS): 6.7 months on MICVO, compared to 4.2 months (95% CI: 2.8-5.6) on the most recent prior therapy for the same 33 patients.
  • Median duration of response (mDOR): 9.2 months; 12-month overall survival probability was 81%.
  • Grade 3 peripheral neuropathy resolution: 83% of the 6 affected patients resolved to Grade 1 or better; 0% did not resolve.
  • Dose capping impact: Among patients receiving a capped dose (N=5), cORR was 60% and Grade 3 treatment-related peripheral neuropathy was 0%, versus 44% and 67%, respectively, for patients dosed above the cap (N=9).
  • Data presented: At the Late-Breaking Oral Presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, on November 19, 2026.

MICVO Phase 1 Monotherapy Results for R/M HNSCC: October 2026 Data Update

According to the filing, Pyxis Oncology (NASDAQ:PYXS) reported updated efficacy and safety data from its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The data cutoff for all figures reported is October 14, 2026. The company disclosed a confirmed objective response rate (cORR) of 39% and a confirmed plus unconfirmed objective response rate (c+uORR) of 52% in 33 evaluable patients, alongside a disease control rate of 94%.

On survival and durability, the filing reported a median progression-free survival of 6.7 months (95% CI: 4.8-9.0), a median duration of response of 9.2 months, and a 12-month overall survival probability of 81%. The filing also presented a comparison showing mPFS on the patients' most recent prior therapy was 4.2 months (95% CI: 2.8-5.6) for the same cohort of 33 patients. By HPV status, cORR was 41% in HPV-positive patients (N=17) and 38% in HPV-unrelated patients (N=16). By line of therapy, cORR was 46% in second-line patients (N=11) and 40% in third-line patients (N=20).

The filing disclosed an incremental safety analysis focused on peripheral neuropathy (PN) and the impact of a dose cap applied to males above 80 kg and females above 70 kg. Among the 6 patients who experienced Grade 3 peripheral neuropathy, 83% resolved to Grade 1 or better and 17% resolved to Grade 2, with 0% not resolving. Any-grade peripheral neuropathy occurred in 68% of patients with prior taxane use (N=25) versus 36% without (N=11). For the dose-capped group (N=5), treatment-related adverse events leading to discontinuation were reported at 20% and Grade 3 treatment-related peripheral neuropathy at 0%, compared to 56% and 67%, respectively, in those dosed above the cap (N=9). The filing noted that forward-looking statements regarding the development of MICVO and clinical trial expectations are subject to the company's cautionary language and applicable risk factors.

What Was Disclosed

Pyxis Oncology filed an 8-K on November 19, 2026, under Items 7.01 and 8.01, disclosing updated Phase 1 monotherapy data for MICVO in R/M HNSCC patients as of October 14, 2026, including efficacy, survival, and safety data, alongside a press release and corporate presentation.